NewAmsterdam Pharma (NAMS) Other Non Operating Income (2023 - 2026)

NewAmsterdam Pharma (NAMS) has 4 years of Other Non Operating Income data on file, last reported at -$1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income fell 137.57% year-over-year to -$1.6 million; the trailing twelve-month figure through Mar 2026 stood at $7.1 million (up 6226.55% YoY), and the FY2025 full-year result was $13.1 million, up 297.86% from the prior year.
• Other Non Operating Income eased to -$1.6 million in Q1 2026, from -$82000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $8.6 million in Q2 2025 to a low of -$7.9 million in Q4 2024.
• A 4-year average of $761692.3 and a median of -$72000.0 in 2023 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income tumbled 1280.56% in 2024 and surged 967.81% in 2025, its largest moves.
• Tracing NAMS's Other Non Operating Income over 4 years: stood at $5.2 million in 2023, then slumped by 250.79% to -$7.9 million in 2024, then jumped by 98.96% to -$82000.0 in 2025, then slumped by 1867.07% to -$1.6 million in 2026.
• Business Quant data shows NAMS's Other Non Operating Income at -$1.6 million in Q1 2026, -$82000.0 in Q4 2025, and $218000.0 in Q3 2025.